Darolutamidi yhdessä ADT- ja sädehoidon kanssa vähensi 58 prosentilla syövän leviämisen tai kuoleman vaaraa potilailla, joilla on suuri eturauhassyövän uusiutumisen riski
ORION OYJ LEHDISTÖTIEDOTE 24.10.2026 KLO 9.30
Covered in this story
Call it yourself
No calls on $ADT yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on ADT →Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.